4.5 Article

Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity

Journal

BIOCHEMICAL JOURNAL
Volume 406, Issue -, Pages 203-207

Publisher

PORTLAND PRESS LTD
DOI: 10.1042/BJ20070664

Keywords

atherosclerosis; coronary heart disease; hypercholesterolaemia; low-density lipoprotein receptor (LDL-R); proprotein convertase subtilisin/kexin 9 (PCSK9); trans-assembly

Ask authors/readers for more resources

PCSK9 (proprotein convertase subtilisin/kexin 9) is a secreted serine protease that regulates cholesterol homoeostasis by inducing post-translational degradation of hepatic LDL-R [\LDL (low-density lipoprotein) receptor]. Intramolecular autocatalytic processing of the PCSK9 zymogen in the endoplasmic reticulum results in a tightly associated complex between the prodomain and the catalytic domain. Although the autocatalytic processing event is required for proper secretion of PCSK9, the requirement of proteolytic activity in the regulation of LDL-R is currently unknown. Co-expression, of the prodomain and the catalytic domain in trans allowed for production of a catalytically inactive secreted form of PCSK9. This catalytically inactive PCSK9 was characterized and shown to be functionally equivalent to the wild-type protein in lowering cellular LDL uptake and LDLR levels. These findings suggest that, apart from autocatalytic processing, the protease activity of PCSK9 is not necessary for LDL-R regulation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available